Entera Bio Ltd.

ENTX

IL0011429839

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.98 ^USD	-1.00%		-0.50%	+230.00%

Apr. 08	Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	CI
Mar. 26	Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	CI

Entera Bio Ltd. announced that it has received $6.610594 million in funding

December 21, 2023

On December 22, 2023, Entera Bio Ltd., closed the transaction.

The company has received $6,610,604 pursuant to Regulation D and included participation from 52 investors.

Latest news about Entera Bio Ltd.

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	Apr. 08	CI
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	Mar. 26	CI
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Top Premarket Gainers	Jan. 18	MT
Top Premarket Gainers	Jan. 17	MT
Entera Bio Ltd. announced that it has received $6.610594 million in funding	Dec. 21	CI
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding	Dec. 19	CI
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform	Nov. 29	CI
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide Phase 3 Program	Nov. 09	CI
Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting	23-10-16	CI
Entera Bio Ltd. Announces Collaboration with OPKO Biologics, Inc. to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes	23-09-12	CI
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research Annual Meeting	23-08-16	CI
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Entera Bio Ltd Adds Haya Taitel to its Board of Directors	23-06-07	CI
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics	23-05-03	CI
Steven R. Goldstein Joins Entera Bio Ltd.'s Clinical and Scientific Advisory Board	23-04-26	CI
Entera Bio Ltd. Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program	23-04-03	CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Entera Bio Ltd. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Entera Bio Regains Compliance with Nasdaq Listing Requirements	23-03-23	MT
Entera Bio Says US FDA Agreed to Type D Meeting Review of Phase 3 Trial Protocol for Osteoporosis Candidate	23-02-15	MT
Entera Bio Ltd. Announces U.S. Food and Drug Administration Acceptance of Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets	23-02-15	CI

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.98 USD

Average target price

10 USD

Spread / Average Target

+405.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENTERA BIO LTD.	+230.00%	70.25M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Entera Bio Ltd.

Equities

ENTX

IL0011429839

Biotechnology & Medical Research

Entera Bio Ltd. announced that it has received $6.610594 million in funding

Latest news about Entera Bio Ltd.

Chart Entera Bio Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs